Viewing Study NCT03650257


Ignite Creation Date: 2025-12-24 @ 6:33 PM
Ignite Modification Date: 2026-02-26 @ 6:53 AM
Study NCT ID: NCT03650257
Status: UNKNOWN
Last Update Posted: 2020-03-12
First Post: 2018-08-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Sponsor: Cure&Sure Biotech Co., LTD
Organization:

Study Overview

Official Title: A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Status: UNKNOWN
Status Verified Date: 2020-02
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
Detailed Description: RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells.

Overall Goals:

\- to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome.

Primary Aim:

\- to further evaluate effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.

Secondary Aims:

to study the immune response to vaccination, to monitor clinical responses , to further the safety of vaccine.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: